Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is the kind of article that we want to see. It is a legitimate research article. The kind of report that the major brokerage houses access on a regular basis.
Nice article from Research Connect
http://www.researchconnect.com/downloadreport.asp?RepID=28960
Research Expert: Kraws, Jeffrey
Chief Executive Officer
Crystal Research Associates, LLC
Report Title: BioCurex, Inc. (BOCX-OTC.BB): Novel, Widespread Cancer Marker to Improve Cancer Diagnostics (04/11/08)
Report Summary: BioCurex, Inc. ("BioCurex" or "the Company") is a biotechnology company developing products for cancer diagnosis, imaging, and therapy that target a global oncology market forecast to reach over $50 billion by 2009. The Company uses a novel, patented technology based on the RECAF™ cancer marker discovered by Dr. Ricardo Moro-Vidal, BioCurex's chief executive officer (CEO), president, and founder. RECAF™ is a molecule found on malignant cells but absent from most normal or benign cells. BioCurex believes that the detection of this molecule in tissue or serum samples is the foundation for new cancer diagnostic tests and imaging techniques. The RECAF™ marker has been found on every cancer tissue that BioCurex has studied to date, including on many common, severe cancers: breast, lung, gastric, prostate, and leukemia. This characteristic indicates that RECAF™ is capable of detecting more than one type of cancer, which is a limitation of many currently available cancer markers. The Company's RECAF™ technology is reported to have high levels of clinical sensitivity and specificity (measures of cancer marker accuracy), successfully detecting over 90% of cancer in blood and tissue samples. A serum-based assay using RECAF™ recently identified twice as many prostate cancers as the current standard for prostate cancer detection, the prostate-specific antigen (PSA) test. In early 2006, a RECAF™-based test also detected 90% to 93% of Stage I and Stage II (early stage) breast cancer samples, without any false positives. This data supports BioCurex's aim of reducing human suffering through the early detection of cancer or cancer recurrence after treatment. Moreover, due to its ability to differentiate between cancerous and normal cells, RECAF™ technology may facilitate the administration of targeted therapeutics that attack cancer cells but do not damage healthy tissue.
Report Date: Thursday, April 10, 2008
My problem with BOCX is this: Even as a share holder of 50K shares, I have yet to receive either an annual statement, a notice of share holder meeting, or a proxy vote ballot. What is up with that? I would definitely vote our dear dentist off of the board if given an opportunity to do so.
I also think that issuance of more stock is normally an issue that requires share holder approval. Am I mistaken?
The lack of information coming from BOCX has been the focus of a large part of the discussion recently. Neither BOCX or it's licensed partners have been very forthcoming with updates or even acknowlegement to BOCX stock holders. I am sure that you aren't insinuating that you can influence that deficiency. The charts are very pretty and now that I know how to hide them, they do not present an issue for me. One day, when BOCX trades above it's current range and volume, the charts will offer some value and I will probably use them.
I am honestly not sure what hard work you are referring to. Your's personally, IH's, or BOCX's. If you are referring to that of BOCX, then yes, I do appreciate the work they have done. I am no newcomer either to IH (over 2 years) BOCX (over 4 years). I am one of the long term investors that you referred to. As far as NEW longterm investors coming on board, well...that will only occur when BOCX becomes a real company, with real BOD, a real income stream, and gets itself onto a real exchange.
Thanks. That fixed it for me.
Please remove the charts from the header of the discussion board. It is not helpful and only serves to clutter up what should remain simple interface for the time being.
Please explain.
BTW - Who ever sold 100 at .53, I hope ou enjoyed your "Happy Meal"
There appears to be a "sweet spot" for trading this morning. Buy at .53 and sell at .58 in 1000 share lots. What the heck, may as well play the bounce.
It did fill at .57. I had reduced the order from 10k to 5k when it filled.
I have had an order for 10k at .57 out there for 3 hours without even a nibble. I did see where someone got filled at .57 though.
I've already done that previously so it's your turn.
In the mean time share price is screaming "I've fallen and I can't get up!"
Oh I am well aware of the current state and why the share price is dropping again. I was actually just being a little tongue-in-cheek about the trend after all of the excitement over the last couple of weeks.
BTW, I have been pinging the major news outlets (ABC, NBC, CBS, and FOX) with the press releases published since the ISOBM. To date, I have not even recieved as much as an acknowledgement about the submission. I do have some inside contacts at the local news level and plan on putting a bug in the ear of a few of those folks. Local is better than nothing and news has to start somewhere.
Darn it! Here I thought we were off to the races and now it looks like we are slipping back into the doldrums again.
It was exciting because I bought 25000 at .23 and sold 25000 at 3.75. I then bought a new 350z as a "whoohah" with 55k left over for reinvestment and taxes.
That was exciting!
Profit is profit and that is the name of the game.
I have been in BOCX since the later part of 2003 and this is the first real excitement I have felt since the 2004 spike to 3.90. I sold at that time and have bought back in several times since then. I think we are finally going to see the fruits of our patience during the many bleak and uncertain times.
It's nice to see some opening volume for a change
Search listed nothing under Biocurex or under Abbott with RECAF
Here is your source of price / volume increase
http://www.smallcapnetwork.com/scb/?p=1173
Then GET OUT!
It is a given that this is a y/n type test with a margin of error. The legal buffer in this case is the fact that a physician administers the test, May or may not share the accuracy data with the patient, and the doc (not the patient), makes an educated determination based on the results.
TedF: Does anyone think that a test indicating someone DOES NOT have cancer could be more problematic than a test which indicates one DOES have cancer?
I'm sorry but I don't understand your question. This test is a yes/no result test so it says either yes you do or no you don't.
Those of you that have a relationship with someone inside of BOCX might want to give them a call and get their thoughts and feeling about the GE news. A little insider insight may at least give us a feel for what the internal response to the news is.
Admittedly, the company needs to get their reporting act together before they become a profitable organization. Once they become a profitable going concern is when financial restatements have serious repercussions on the stock price and investor confidence.
At present, it is a given that BOCX is cash consumer that is geared to run in the red. Because of that, a financial restatement for the adjusted value of mis-reported equities trades does not particularly bother me outside of the fact that the weakness in the process and audit trail leaves the door open for someone to rob the cookie jar.
The internal auditors said nothing about the SEC filings or their accuracy except that there is the possibility of financial restatement(s) if BOCX identifies errors in securities transactions. They referred to a material weakness in the accounting controls within Biocurex that had to be referenced in filings to comply with Sarbanes-Oxley
For those of you holding NFLD that didn't sell at 17+, my condolences. NFLD was crushed this AM with a 53% loss to $5.40 due to negative trial data
And that increase reflects what percent of outstanding shares as opposed to the previous measurment?
Agreed, The Investor Relations contact can only give out the approved PR answers.
It can however, offer a little bit of insight about what is absolute fact
That would have been better since my stop executed at 13.30. I could have re-bought really really cheap
They sure did get off badly. Triggerd a 10% trailing stop order and now I have had to rebuy in the gap over where it sold. Dangit!
There has been less trading volume on the OTCBB than there was on the Pinks
Oops, I meant Bocxman. Sorry
Bocxan, I agree with the "secret sauce" analogy presented by tommyb. The fact that there are proprietary processes and methods that are needed in order to use RECAF technology that are not included in the patent filings, puts BOCX in the position of being able to license RECAF to a company based on the proprietary info. In essence, a company would be asking for a license to RECAF in order to obtain that knowledge. In a country where RECAF is not patented, the proprietary knowledge that goes with a license would still maintain the value of licensing agreement. If RECAF is a car then the proprietary aspect are the keys.
RTM wrote: "We are all on the train. But it just keeps sitting at the station"
So pull out your deck of cards and play a few hands in anticipation of the journey. In other words "ARE WE THERE YET"? is a question reserved for children without enough understanding of time and distance to know how to extrapolate the answer. Chill out, every journey takes time.
Not likely since the big transactions were purchases not sales.
What's up with the high volume and large lot purchases this morning?
I like the volume as well (even if 12.5% of it is my own purchase. (Yeah, I gave em .58)). I'm just not sure I want to visit the 52 week low again.
Trying to buy shares of bocx has always been a crap shoot at best. The inconsistency is maddening
I can't get 5000 @ .56 but someone got 1500 @ .55. Go figure